JP2022536345A5 - - Google Patents

Info

Publication number
JP2022536345A5
JP2022536345A5 JP2021573421A JP2021573421A JP2022536345A5 JP 2022536345 A5 JP2022536345 A5 JP 2022536345A5 JP 2021573421 A JP2021573421 A JP 2021573421A JP 2021573421 A JP2021573421 A JP 2021573421A JP 2022536345 A5 JP2022536345 A5 JP 2022536345A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
fusion protein
variant polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536345A (ja
JP7607938B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037644 external-priority patent/WO2020252418A2/en
Publication of JP2022536345A publication Critical patent/JP2022536345A/ja
Publication of JP2022536345A5 publication Critical patent/JP2022536345A5/ja
Priority to JP2024216112A priority Critical patent/JP2025063029A/ja
Application granted granted Critical
Publication of JP7607938B2 publication Critical patent/JP7607938B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573421A 2019-06-14 2020-06-13 がんの治療ための新規インターロイキン-2バリアント Active JP7607938B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024216112A JP2025063029A (ja) 2019-06-14 2024-12-11 がんの治療ための新規インターロイキン-2バリアント

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861651P 2019-06-14 2019-06-14
US62/861,651 2019-06-14
US201962947806P 2019-12-13 2019-12-13
US62/947,806 2019-12-13
PCT/US2020/037644 WO2020252418A2 (en) 2019-06-14 2020-06-13 Novel interleukin-2 variants for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024216112A Division JP2025063029A (ja) 2019-06-14 2024-12-11 がんの治療ための新規インターロイキン-2バリアント

Publications (3)

Publication Number Publication Date
JP2022536345A JP2022536345A (ja) 2022-08-15
JP2022536345A5 true JP2022536345A5 (cg-RX-API-DMAC7.html) 2023-08-07
JP7607938B2 JP7607938B2 (ja) 2025-01-06

Family

ID=73782252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573421A Active JP7607938B2 (ja) 2019-06-14 2020-06-13 がんの治療ための新規インターロイキン-2バリアント
JP2024216112A Pending JP2025063029A (ja) 2019-06-14 2024-12-11 がんの治療ための新規インターロイキン-2バリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024216112A Pending JP2025063029A (ja) 2019-06-14 2024-12-11 がんの治療ための新規インターロイキン-2バリアント

Country Status (9)

Country Link
US (1) US20220235109A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983433A4 (cg-RX-API-DMAC7.html)
JP (2) JP7607938B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260102840A (cg-RX-API-DMAC7.html)
CN (2) CN120795117A (cg-RX-API-DMAC7.html)
AU (1) AU2020291942B2 (cg-RX-API-DMAC7.html)
CA (1) CA3143034A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021015834A (cg-RX-API-DMAC7.html)
WO (1) WO2020252418A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CA3098930A1 (en) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
CN111423510B (zh) * 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
WO2022012428A1 (zh) * 2020-07-14 2022-01-20 迈威(上海)生物科技股份有限公司 抗pd-1抗体及其稳定制剂
KR20230060514A (ko) * 2020-09-01 2023-05-04 다케다 야쿠힌 고교 가부시키가이샤 인터루킨-2 뮤테인 및 이의 용도
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202241932A (zh) * 2020-12-23 2022-11-01 美商默沙東藥廠 用於治療自體免疫及發炎性疾病之il-2突變蛋白
CN117015555A (zh) * 2021-03-09 2023-11-07 豪夫迈·罗氏有限公司 Pd-1靶向il-2变体免疫缀合物和抗tyrp1/抗cd3双特异性抗体的组合疗法
AU2022231874A1 (en) * 2021-03-09 2023-07-27 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
CA3213751A1 (en) * 2021-03-31 2022-10-06 Ziyang Zhong Fusion proteins, pharmaceutical compositions, and therapeutic applications
CN112724263B (zh) * 2021-04-02 2021-08-03 上海偌妥生物科技有限公司 改造抗cd20单克隆抗体以提高其药物疗效的方法及其应用
KR20240019786A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
EP4376870A4 (en) * 2021-07-28 2025-07-23 Anwita Biosciences Inc INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
CN113831402A (zh) * 2021-07-30 2021-12-24 西安龙腾景云生物科技有限公司 一种人白细胞介素2变体及其用途
MX2024003140A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Construcciones, composiciones y metodos de multabody optimizados.
MX2024003139A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Multabody dirigido a dr5 para el tratamiento del cancer.
JP7864826B2 (ja) * 2021-09-22 2026-05-25 フォートビタ バイオロジクス(シンガポール)プライベート リミティド インターロイキン2変異体およびその融合タンパク質
WO2023076927A1 (en) * 2021-10-27 2023-05-04 Anwita Biosciences, Inc. Il-2 fusion proteins, pharmaceutical compositions, and therapeutic applications
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
WO2024104444A1 (zh) * 2022-11-17 2024-05-23 南通壹宸生物医药科技有限公司 Il-2突变体及其应用
KR102893442B1 (ko) * 2022-12-23 2025-12-01 가톨릭대학교 산학협력단 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
EP4689123A1 (en) * 2023-03-29 2026-02-11 WuXi Biologics Ireland Limited Il-2 variants with improved stability and compositions thereof
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
CN121969385A (zh) * 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
US20260083857A1 (en) * 2024-09-23 2026-03-26 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
JP6640834B2 (ja) * 2014-08-11 2020-02-05 デリニア, インコーポレイテッド 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体
IL304950A (en) * 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CN119264274A (zh) * 2017-10-12 2025-01-07 免疫苏醒公司 Vegfr-抗体轻链融合蛋白
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof

Similar Documents

Publication Publication Date Title
JP7317159B2 (ja) キメラ抗原受容体及びその使用方法
JP2022536347A5 (cg-RX-API-DMAC7.html)
Jazayeri et al. Fc-based cytokines: prospects for engineering superior therapeutics
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP7575100B2 (ja) 免疫細胞活性化のための二重特異性抗体
JP2025166053A (ja) 調整可能な親和性を有する免疫調節タンパク質
JP2022109915A (ja) Cd80バリアント免疫調節タンパク質およびその使用
JP2023506452A5 (cg-RX-API-DMAC7.html)
CA2927543C (en) Peptidic chimeric antigen receptor t cell switches and uses thereof
JP2023506454A5 (cg-RX-API-DMAC7.html)
KR102724621B1 (ko) 이종이량체화 Ig 도메인
US20130011401A1 (en) Soluble proteins for use as therapeutics
JP2023138962A (ja) Ctla-4変異型免疫調節タンパク質およびそれらの使用
JP2013531470A5 (cg-RX-API-DMAC7.html)
JP2020511143A5 (cg-RX-API-DMAC7.html)
JP2019533449A (ja) 多量体il−15に基づく分子
WO2014145159A2 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
CN106999587A (zh) 多价中间表位,中间表位结合抗体及其用途
CA3173414A1 (en) Pd-1 agonist multimeric binding molecules
TW202334204A (zh) 條件性活化之抗原結合多肽複合物及其使用方法
JP2024507693A (ja) 二重特異性抗体
US20240034808A1 (en) Antigen binding polypeptide complexes containing extracellular domains of tnfsf ligands
JP2023532278A5 (cg-RX-API-DMAC7.html)
KR20230141839A (ko) 전하쌍을 갖는 이중 특이성 항체 및 이의 용도
KR20230098334A (ko) Cldn6 및 cd3에 선택적으로 결합하는 폴리펩디드 작제물